Burzynski Research (BZYR)
Burzynski Research Institute, Inc. is a biotechnology company focused on the research and development of antineoplaston drugs for the treatment of various cancers. Under the Antineoplastons name, the company works with medical chemical compounds that include growth-inhibiting peptides, amino acid derivatives, and organic acids. Its activities also include research, production, marketing, promotion, and sale of these compounds, along with consulting services. Founded in 1977, the company is headquartered in Houston, Texas. Burzynski Research common stock trades on OTC Markets under the symbol BZYR.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-BZYR
|
$0.0018
|
-10.0% Downside
|
Fair
|
Not available
|
Not available
|
Weak
|
0.0%
|
October 7, 2026
|
256.324 K
|
260.731 K
|
0.0%
|
19.0%
|
-82,552.6
|
20.0%
|
